All In Biotech

Drug Trial Radar · NCT02149173

F-18 FES PET/CT in Measuring Hormone Expression in Patients With Primary, Recurrent, or Metastatic Breast Cancer Undergoing Endocrine-Targeted Therapy

Serial [F-18] Fluoroestradiol (FES) PET Imaging to Evaluate Endocrine-Targeted Therapy

Last checked: Nov 20, 2026Latest source record: Jun 30, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

29

Actual

Start

Sep 15, 2010

Primary completion

Dec 27, 2018

Study completion Jan 13, 2021

Sponsor

Lead sponsor
University of WashingtonAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Cancer Institute (NCI)
First posted
May 29, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This clinical trial studies use of F-18 16 alpha-fluoroestradiol (\[F-18\] FES) positron emission tomography (PET)/computed tomography (CT) in measuring tumor hormone receptor expression in patients undergoing endocrine-targeted therapy for newly diagnosed breast cancer or breast cancer that has come back or spread to other places in the body. Comparing results of diagnostic procedures done before, during, and after hormone therapy may help measure a patient's response to treatment.

Conditions

  • Estrogen Receptor Positive
  • Recurrent Breast Carcinoma
  • Stage IV Breast Cancer AJCC v6 and v7

Interventions

  • Computed TomographyProcedure

    Undergo F-18 FES PET/CT

  • Computed TomographyProcedure

    Undergo FDG PET/CT

  • F-18 16 Alpha-FluoroestradiolDrug

    Undergo F-18 FES PET/CT

  • Fludeoxyglucose F-18Drug

    Undergo FDG PET/CT

  • Laboratory Biomarker AnalysisOther

    Correlative studies

  • Positron Emission TomographyProcedure

    Undergo F-18 FES PET/CT

  • Positron Emission TomographyProcedure

    Undergo FDG PET/CT

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in F-18 16 Alpha-fluoroestradiol (FES) Standardized Uptake Value (SUV), Assessed by a One-sample Test of the Percent Change in FES SUVTime frame: from time of first F-18 FES-PET/CT scan to time of second or third F-18 FES-PET/CT scan (approximately 2-8 weeks)
  2. F-18 16 Alpha-fluoroestradiol (FES) UptakeTime frame: from time of first F-18 FES-PET/CT scan to time of second or third F-18 FES-PET/CT scan (approximately 2-8 weeks)
  3. Proportion of Patients Experienced a Threshold in Percentage Change, or Surpassed a Targeted Follow-up F-18 16 Alpha-fluoroestradiol (FES) Standardized Uptake Value (SUV)Time frame: from time of first F-18 FES-PET/CT scan to time of second or third F-18 FES-PET/CT scan (approximately 2-8 weeks)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fred Hutch/University of Washington Cancer Consortium

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.